Association of the 4 g/5 g polymorphism of plasminogen activator inhibitor-1 gene with sudden sensorineural hearing loss. A case control study

BMC Ear, Nose and Throat Disorders

Tae J Yoo²  Alessandro Martini³  Micol Busi³  Silvia Palma¹  Chun Cai²  David Cho⁴  Joseph Kang⁴  Chio Yokose⁴  Il Soo Kim⁴  Haimei Chen⁴  Seong Ho Cho⁵ 

[1] University of Modena, Modena, Italy;University of Tennessee, College of Medicine, Memphis, TN, USA;University of Ferrara, Ferrara, Italy;Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, 676 N. St Clair street #14028, Chicago, IL, 60611, USA;Kyung Hee University, College of Medicine, Seoul, Korea

关键词: 4 G/5 G polymorphism;    Plasminogen activator inhibitor-1;    Sudden hearing loss;   

Others  :  862805
DOI  :  10.1186/1472-6815-12-5

 received in 2011-12-12, accepted in 2012-05-18,  发布年份 2012

【 摘 要 】

Background

The 5 G/5 G genotype of PAI-1 polymorphism is linked to decreased plasminogen activator inhibitor-1 (PAI-1) levels and it has been suggested that lower PAI-1 levels may provide protective effects on inflammation, local microcirculatory disturbance, and fibrotic changes, which are likely associated with development of sudden sensorineural hearing loss (SSNHL).

Methods

The association of the 4 G/5 G PAI-1 polymorphism with the development and clinical outcome of SSNHL is evaluated via a case control study. 103 patients with SSNHL and 113 age and sex-matched controls were enrolled at University of Ferrara, Italy and hearing loss outcome was measured at least 3 months after the onset of hearing loss. DNA was isolated from peripheral blood using the QIAamp kit and the 4 G/5 G polymorphism in the −675 promoter region was genotyped with an allele-specific PCR. Genotype distribution was tested in patients and compared to controls by chi-square and odd-ratio analysis. The codominant and recessive models were used for the multiple logistic regression analyses of the PAI-1 gene allele.

Results

In this population, 5 G/5 G genotype had a two-time lower frequency in SSNHL patients compared to healthy controls (15.5% vs 30.1%) and was associated with decreased odds compared to 4 G/5 G genotype (OR 0.37, 95% CI 0.19-0.75, p = 0.005). In addition, the patients with 5 G/5 G genotype showed a trend of more than 2 times higher ratio of hearing recovery (> 20 dB) after systemic corticosteroid treatment compared to 4 G/5 G genotype (OR 2.3, 95% CI 0.32 - 16.83, p = 0.39), suggesting a better clinical outcome.

Conclusions

The 5 G/5 G genotype of PAI-1 may be associated with a reduced risk of SSNHL in the Italian population.

【 授权许可】

   
2012 Cho et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Stachler RJ: Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012, 146:S1-S35.
• [2]Kuhn M, Heman-Ackah SE, Shaikh JA, Roehm PC: Sudden Sensorineural Hearing Loss: A Review of Diagnosis, Treatment, and Prognosis. Trends Amplif 2011, 15:91-105.
• [3]Chau JK, Lin JR, Atashband S, Irvine RA, Westerberg BD: Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope 2010, 120:1011-1021.
• [4]Lazarini PR, Camargo AC: Idiopathic sudden sensorineural hearing loss: etiopathogenic aspects. Braz J Otorhinolaryngol 2006, 72:554-561.
• [5]Cadoni G: Coenzyme Q 10 and cardiovascular risk factors in idiopathic sudden sensorineural hearing loss patients. Otol Neurotol 2007, 28:878-883.
• [6]Marcucci R, et al.: Cardiovascular and thrombophilic risk factors for idiopathic sudden sensorineural hearing loss. J Thromb Haemost 2005, 3:929-934.
• [7]Capaccio P, et al.: Genetic and acquired prothrombotic risk factors and sudden hearing loss. Laryngoscope 2007, 117:547-551.
• [8]Ballesteros F, et al.: Is there an overlap between sudden neurosensorial hearing loss and cardiovascular risk factors? Audiol Neurootol 2009, 14:139-145.
• [9]Aimoni C, et al.: Diabetes, cardiovascular risk factors and idiopathic sudden sensorineural hearing loss: a case–control study. Audiol Neurootol 2010, 15:111-115.
• [10]Gorur K, Tuncer U, Eskandari G, Ozcan C, Unal M, Ozsahinoglu C: The role of factor V Leiden and prothrombin G20210A mutations in sudden sensorineural hearing loss. Otol Neurotol 2005, 26:599-601.
• [11]Rudack C, Langer C, Junker R: Platelet GPIaC807T polymorphism is associated with negative outcome of sudden hearing loss. Hear Res 2004, 191:41-48.
• [12]Cadoni G, et al.: Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients. Ann Otol Rhinol Laryngol 2006, 115:195-200.
• [13]Mosnier I, et al.: Cardiovascular and Thromboembolic Risk Factors in Idiopathic Sudden Sensorineural Hearing Loss: A Case–control Study. Audiol Neuro-Otol 2011, 16:55-66.
• [14]Suzuki J, et al.: Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases. Expert Opin Investig Drugs 2011, 20:255-264.
• [15]de Paula Sabino A: Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke. Mol Biol Rep 2011, 38:5355-5360.
• [16]Ma Z, Paek D, Oh CK: Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Exp Allergy 2009, 39:1136-1144.
• [17]Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK: Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 2000, 165:3154-3161.
• [18]Cho S, et al.: Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma. Ann Allergy Asthma Immunol 2011, 106:371-377.
• [19]Yildiz Z, Ulu A, Incesulu A, Ozkaptan Y, Akar N: The importance of thrombotic risk factors in the development of idiopathic sudden hearing loss. Clin Appl Thromb Hemost 2008, 14:356-359.
• [20]Mora R, Mora F, Mora M, Barbieri M, Yoo TJ: Restoration of hearing loss with tissue plasminogen activator. Case report. Ann Otol Rhinol Laryngol 2003, 112:671-674.
• [21]Schuknecht HF, Kimura RS, Naufal PM: The pathology of sudden deafness. Acta oto-laryngologica 1973, 76:75-97.
• [22]Gentilini D, et al.: Plasminogen activator inhibitor-1 4 G/5G polymorphism and susceptibility to endometriosis in the Italian population. Eur J Obstet Gynecol Reprod Biol 2009, 146:219-221.
• [23]Garcia-Segarra G, et al.: Increased mortality in septic shock with the 4 G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 2007, 33:1354-1362.
• [24]Mansfield MW, Stickland MH, Grant PJ: Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995, 74:1032-1034.
• [25]Cho SH, et al.: Possible role of the 4 G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol 2001, 108:212-214.
• [26]Falk G, Almqvist A, Nordenhem A, Svensson H, Wiman B: Allele-Specific Pcr for Detection of a Sequence Polymorphism in the Promoter Region of the Plasminogen-Activator Inhibitor-1 (Pai-1) Gene. Fibrinolysis 1995, 9:170-174.
• [27]Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A: Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999, 93:2449-2453.
• [28]Akar N, Yilmaz E, Akar E, Avcu F, Yalcin A, Cin S: Effect of plasminogen activator inhibitor-1 4 G/5 G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res 2000, 97:227-230.
• [29]Mercier E, et al.: The 20210A allele of the prothrombin gene is an independent risk factor for perception deafness in patients with venous thromboembolic antecedents. Blood 1999, 93:3150-3152.
• [30]Aso Y: Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007, 12:2957-2966.